BENGALURU (Reuters) – Pharmaceutical company Granules India Ltd reported a 23% rise in third-quarter profit on Tuesday, propelled by strong demand for the painkiller drug Paracetamol.
Consolidated profit rose to 1.24 billion rupees ($15.22 million) for the three months ended Dec. 31, from 1.01 billion rupees a year earlier.
Consolidated revenue for the company rose nearly 15% to 11.46 billion rupees, “primarily driven by higher Paracetamol API sales in the US,” the company said in an exchange filing.
“Opportunities in Paracetamol are likely to continue and our geography expansion strategy in Europe is likely to yield higher turnover and EBITDA in future periods,” Chairman Krishna Prasad Chigurupati said.
Granules, which also makes anti-inflammatory drug Ibuprofen, said 45.6% of its revenue came from finished dosages – the final ready-for-consumption product – its biggest segment.
Active pharmaceutical ingredients and pharmaceutical formulation intermediates contributed 35.8% and 18.6%, respectively, to the drug manufacturer’s revenue.
Shares of the company climbed as much as 1.5% to 316.8 rupees, hitting a one-week high after the results. They declined 5.2% in 2022, compared with an 11.4% fall in the Nifty Pharma index.
($1 = 81.4670 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru; Editing by Janane Venkatraman)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.